Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: Twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 387-395

  Healy, E ^a   Bentley, A ^b   Fidler, C ^b   Chambers, Colette ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Decision Resources Group   (United Kingdom)

^c ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG COST; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; OINTMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNCERTAINTY; UNITED KINGDOM;

ADULT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; STATE MEDICINE; TACROLIMUS;

EID: 79551495578     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10141.x     Document Type: Article

References (55)

1. Leung DY,. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-76.
2. Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005; 22: 192-9.
3. Mancini AJ, Kaulback K, Chamlin SL,. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2008; 25: 1-6.
4. Williams HC, Strachan DP,. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 1998; 139: 834-9.
5. Darsow U, Lubbe J, Taieb A, et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-95.
6. Lubach D, Bensmann A, Bornemann U,. Steroid-induced dermal atrophy. Investigations on discontinuous application. Dermatologica 1989; 179: 67-72.
7. Fisher DA,. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123-6.
8. Turpeinen M, Salo OP, Leisti S,. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986; 115: 475-84.
9. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-44.
10. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28-38.
11. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64.
12. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-57.
13. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55. (Pubitemid 34234209)
14. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46. (Pubitemid 34234208)
15. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006.
16. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816-21.
17. Soter NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39-46.
18. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 151 (Suppl. 70): 3-27. (Pubitemid 40023628)
19. Goa KL,. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review. Drugs 1988; 36 (Suppl. 5): 51-61.
20. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53: S186-94.
21. Koo JY, Fleischer AB Jr, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53: S195-205.
22. Mori M, Pimpinelli N, Giannotti B,. Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio. Drug Saf 1994; 10: 406-12.
23. Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0·1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942-51.
24. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76.
25. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-9. (Pubitemid 40489494)
26. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0·1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005; 125: 68-71. (Pubitemid 40981425)
27. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70.
28. Remitz A, Reitamo S,. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf 2009; 8: 501-6.
29. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282-9.
30. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0·03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-56.
31. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0·1% tacrolimus ointment. Allergy 2008; 63: 742-50.
32. Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008; 58: 990-9.
33. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-32.
34. Rawlins MD, Culyer AJ,. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224-7.
35. Astellas Pharma Europe R&D. Clinical study on tacrolimus ointment over the long term 'CONTROL study-adults'. Clinical study report. Study FG-506-06-40. Data on file, 2007.
36. Astellas Pharma Europe R&D. Clinical study on tacrolimus ointment over the long term 'CONTROL study-children'. Clinical study report. Study FG506-06-41. Data on file, 2007.
37. Garside R, Stein K, Castelnuovo E, et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005; 9: iii, xi-xiii, 1-230.
38. Loftus EV Jr, Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009; 21: 1302-9.
39. Levy AR, Christensen TL, Johnson JA,. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008; 6: 73.
40. MIMS. October 2009.
41. IMS Health. Astellas, data on file. February 2010.
42. Department of Health. NHS Reference costs 2007-2008. Available at: (last accessed 3 December 2010).
43. Curtis L,. Unit costs of health and social care 2008. Canterbury, U.K.: Personal Social Services Research Unit, 2008.
44. Morris S, Devlin N, Parkin D,. Economic Analysis in Health care. Oxford: John Wiley & Sons, Ltd, 2007.
45. National Institute for Health and Clinical Excellence. Guide to the methods for technology appraisal, June 2008. Available at: (last accessed 3 December 2010).
46. Thaci D, Chambers C, Sidhu M, et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol 2010; 24: 1040-6.
47. Wollenberg A, Sidhu MK, Odeyemi I, et al. Economic evaluation of maintenance treatment with tacrolimus 0·1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008; 159: 1322-30.
48. Danby SG, Cork MJ,. A new understanding of atopic dermatitis: the role of epidermal barrier dysfunction and subclinical inflammation. J Clin Dermatol 2010; 1: 33-46.
49. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367.
50. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-28.
51. Ormerod AD,. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153: 701-5.
52. Richardson K,. Topical pimecrolimus, tacrolimus, and the risk for cancer: an expert interview with Lawrence Eichenfield, MD. Medscape Dermatol 2005; 6. Available at: (last accessed 12 February 2010).
53. Margolis DJ, Hoffstad O, Bilker W,. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-95.
54. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16.
55. Arana A, Wentworth CE, Fernandez-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol 2010; 143: 1036-43.